China’s National Healthcare Security Administration has added FibroGen’s (FGEN +2.9%) roxadustat to its National Reimbursement Drug List for the treatment of anemia in chronic kidney disease patients, both dialysis-dependent and non-dialysis-dependent.
The company is collaborating with AstraZeneca (AZN -0.1%) on development and commercialization there.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.